• |
  • |
  • |
  • |
Donate

Project

STRIDE (REN001-201)

Center:
Fiscal Year:
2024
Contact Information:
Project Description:
Title: STRIDE (REN001-201): A double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with REN001 in patients with primary mitochondrial myopathy Role: Site PI Funding: Reneo Pharmaceuticals April 2021-present Summary: This is a randomized, double-blind, placebo-controlled, parallel group, multi-center, study designed to investigate the efficacy and safety of REN001 administered once daily over a 24-week period to patients with primary mitochondrial myopathy.
Keyword(s):
Core Function(s):
Performing Research or Evaluation, Continuing Education/Community Training
Area of Emphasis
Other
Target Audience:
Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Other
Primary Target Audience Geographic Descriptor:
National
Funding Source:
COVID-19 Related Data:
N/A